EMA Authorised: Zynlonta (loncastuximab tesirine) — Swedish Orphan Biovitrum AB

View source ↗

Summary

EMA authorised Zynlonta (loncastuximab tesirine) for certain B-cell lymphomas with a conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell
• Lymphoma Large B-cell Diffuse

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse;Lymphoma, B-Cell. MAH: Swedish Orphan Biovitrum AB. Decision date: 12/02/2026. Conditional approval